Compare Sea Limited (SE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Summit Therapeutics Inc — how do they compare? Sea Limited trades at $106.01 (market cap $64.73B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Sea Limited is far larger — about 6.2× Summit Therapeutics Inc's market cap, and Sea Limited is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SE | SMMT | |
|---|---|---|
Market Cap | $64.73B | $10.48B |
Sector | Media | Health |
52-Week High | $196.50 | $29.32 |
52-Week Low | $78.16 | $13.05 |
Enterprise Value | $57.78B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $106.26, up 2.12% with a neutral technical signal. The company shows strong revenue growth, reaching $22.94 billion in 2025 with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Analyst sentiment remains bullish with a $131 consensus price target, though insider selling has drawn attention amid a 30% stock decline over the past year.
The outlook is mixed: robust fundamentals and analyst support suggest upside potential, but risks include earnings volatility, competitive pressures, and geopolitical factors affecting sentiment. The stock's valuation at a P/E of 41.61 requires sustained growth to justify current levels, making execution critical for future performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
